<?xml version="1.0" encoding="UTF-8"?>
<!-- generator="FeedCreator 1.8" -->
<?xml-stylesheet href="https://bsi.inscog.eu/lib/exe/css.php?s=feed" type="text/css"?>
<rdf:RDF
    xmlns="http://purl.org/rss/1.0/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
    xmlns:dc="http://purl.org/dc/elements/1.1/">
    <channel rdf:about="https://bsi.inscog.eu/feed.php">
        <title>BSI wiki - purification:tev</title>
        <description></description>
        <link>https://bsi.inscog.eu/</link>
        <image rdf:resource="https://bsi.inscog.eu/lib/exe/fetch.php?media=wiki:dokuwiki.svg" />
       <dc:date>2026-06-01T23:06:15+00:00</dc:date>
        <items>
            <rdf:Seq>
                <rdf:li rdf:resource="https://bsi.inscog.eu/doku.php?id=purification:tev:b_protocol&amp;rev=1698869944&amp;do=diff"/>
                <rdf:li rdf:resource="https://bsi.inscog.eu/doku.php?id=purification:tev:c_protocol&amp;rev=1698869944&amp;do=diff"/>
                <rdf:li rdf:resource="https://bsi.inscog.eu/doku.php?id=purification:tev:faq&amp;rev=1698869942&amp;do=diff"/>
                <rdf:li rdf:resource="https://bsi.inscog.eu/doku.php?id=purification:tev:s_protocol&amp;rev=1698869944&amp;do=diff"/>
                <rdf:li rdf:resource="https://bsi.inscog.eu/doku.php?id=purification:tev:w_protocol&amp;rev=1698869944&amp;do=diff"/>
            </rdf:Seq>
        </items>
    </channel>
    <image rdf:about="https://bsi.inscog.eu/lib/exe/fetch.php?media=wiki:dokuwiki.svg">
        <title>BSI wiki</title>
        <link>https://bsi.inscog.eu/</link>
        <url>https://bsi.inscog.eu/lib/exe/fetch.php?media=wiki:dokuwiki.svg</url>
    </image>
    <item rdf:about="https://bsi.inscog.eu/doku.php?id=purification:tev:b_protocol&amp;rev=1698869944&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2023-11-01T20:19:04+00:00</dc:date>
        <dc:creator>Anonymous (anonymous@undisclosed.example.com)</dc:creator>
        <title>b_protocol</title>
        <link>https://bsi.inscog.eu/doku.php?id=purification:tev:b_protocol&amp;rev=1698869944&amp;do=diff</link>
        <description>Culture et purification TEV

1. Culture

	*  Electrotransformation BL21(DE3) avec plasmide pTEV 
	*  Etalement sur boite LB agar + Kan 30 µg/ml
	*  Quelques colonies prélevées pour ensemencer préculture de 100 ml de LB + kanamycine 30 µg/ml
	*  Culture de 3 x 1 litre de LB Kan 30 µg/ml ensemencée avec la préculture pour avoir DO initiale de 0.1</description>
    </item>
    <item rdf:about="https://bsi.inscog.eu/doku.php?id=purification:tev:c_protocol&amp;rev=1698869944&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2023-11-01T20:19:04+00:00</dc:date>
        <dc:creator>Anonymous (anonymous@undisclosed.example.com)</dc:creator>
        <title>c_protocol</title>
        <link>https://bsi.inscog.eu/doku.php?id=purification:tev:c_protocol&amp;rev=1698869944&amp;do=diff</link>
        <description>Cabrita TEV Purification protocol

Two point mutations were introduced to produce the double mutant L56V/S135G. The mutations were introduced using the QuikChange Site Directed Mutagenesis kit (Stratagene).

	*  The proteins were expressed in BL21pRIPL</description>
    </item>
    <item rdf:about="https://bsi.inscog.eu/doku.php?id=purification:tev:faq&amp;rev=1698869942&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2023-11-01T20:19:02+00:00</dc:date>
        <dc:creator>Anonymous (anonymous@undisclosed.example.com)</dc:creator>
        <title>faq</title>
        <link>https://bsi.inscog.eu/doku.php?id=purification:tev:faq&amp;rev=1698869942&amp;do=diff</link>
        <description>TEV Protease FAQ

----------

What protease inhibitors are known not to affect TEV?

PMSF and AEBSF (1mM), TLCK (1mM), Bestatin (1mg/ml), pepstatin A (1mM), EDTA (1mM), and  E-64 (3mg/ml), “complete” protease inhibitor cocktail (Roche).  Zinc will inhibit the activity of the enzyme at concentrations of 5 mM or greater. Reagents that react with cysteine (e.g., iodoacetamide) are potent inhibitors of TEV protease.</description>
    </item>
    <item rdf:about="https://bsi.inscog.eu/doku.php?id=purification:tev:s_protocol&amp;rev=1698869944&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2023-11-01T20:19:04+00:00</dc:date>
        <dc:creator>Anonymous (anonymous@undisclosed.example.com)</dc:creator>
        <title>s_protocol</title>
        <link>https://bsi.inscog.eu/doku.php?id=purification:tev:s_protocol&amp;rev=1698869944&amp;do=diff</link>
        <description>TEV preparation - Séraphin Lab

j-1

	*  Transform BL21/LysS strain on KanR with optimized TEV plasmid (stock pBS2440).

j

	*  Inoculate 25 ml medium A with one colony at the end of the afternoon.
	*  Grow at 37°C.

j+1

	*  Inoculate 1 L medium A with the 25 ml preculture.</description>
    </item>
    <item rdf:about="https://bsi.inscog.eu/doku.php?id=purification:tev:w_protocol&amp;rev=1698869944&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2023-11-01T20:19:04+00:00</dc:date>
        <dc:creator>Anonymous (anonymous@undisclosed.example.com)</dc:creator>
        <title>w_protocol</title>
        <link>https://bsi.inscog.eu/doku.php?id=purification:tev:w_protocol&amp;rev=1698869944&amp;do=diff</link>
        <description>Expression &amp; Purification of His-TEV(S219V)-Arg

S. Cherry, J. E. Tropea, D. S. Waugh

	*  BL21-RIL cells containing pRK793 are grown at 37 °C in L-broth containing 100 μg/ml ampicillin and 30 μg/ml chloramphenicol.
	*  When the cells reach mid log phase (OD600~0.5), IPTG is added to a final concentration of 1 mM and the temperature is reduced to 30 °C.</description>
    </item>
</rdf:RDF>
